Laclimella (Dienogest, Estradiol Valerate)

The estradiol component supplies estrogen that stabilises the endometrium and suppresses follicular growth, while dienogest, a progestogen, binds to progesterone receptors to block the hypothalamic‑pituitary‑ovarian axis. This prevents the luteinising hormone surge, stops ovulation, thickens cervical mucus and alters the endometrium, collectively preventing fertilisation and implantation.

The dosing regimen for Laclimella is determined by the prescribing healthcare professional based on the product’s approved labeling and the patient’s individual needs. Typically, combined oral contraceptives follow a cyclic schedule, but exact tablet strength, number of active days and any hormone‑free interval are set by the prescriber.

Laclimella is contraindicated during pregnancy because its purpose is to prevent conception. If pregnancy occurs, the product should be discontinued. While limited data exist for breastfeeding, combined oral contraceptives are generally considered compatible with lactation, though clinicians should assess individual risk‑benefit and discuss any potential effects on milk production.

To request Laclimella, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Laclimella contains the specific progestogen dienogest combined with estradiol valerate, offering a hormonal profile that may provide a lower risk of androgen‑related side effects such as acne compared with some older formulations that use levonorgestrel. Efficacy in preventing pregnancy is comparable across approved combined oral contraceptives, while individual tolerability can differ based on the progestogen and estrogen dose.

Laclimella tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture and direct light, and ensure the packaging is tightly closed to maintain tablet integrity throughout the shelf life.

Laclimella is taken orally, usually once daily at the same time each day. The typical regimen involves a series of active tablets followed by a hormone‑free interval, but the exact schedule is defined by the prescribing clinician. Swallow the tablet whole with water; do not split, crush, or chew unless instructed otherwise.

Serious, though rare, risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Additional concerns are severe allergic reactions and hepatic dysfunction. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, chest pain, severe headache, or signs of an allergic reaction.

Laclimella is contraindicated in women with a history of or active thromboembolic disease, uncontrolled hypertension, known or suspected breast or estrogen‑dependent cancers, severe liver disease, or in smokers aged over 35 years. It should also be avoided in individuals with known hypersensitivity to dienogest, estradiol valerate, or any excipients in the tablet.